​

Akoya Biosciences (AKYA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AKYA Stock Forecast

Akoya Biosciences (AKYA) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $2.40, with a high of $2.40 and a low of $2.40. This represents a 118.18% increase from the last price of $1.10.

$1 $2 $3 $4 $5 $6 High: $2.4 Avg: $2.4 Low: $2.4 Last Closed Price: $1.1

AKYA Stock Rating

Akoya Biosciences stock's rating consensus is Hold, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (42.86%), 4 Hold (57.14%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 7 0 4 3 Strong Sell Sell Hold Buy Strong Buy

AKYA Price Target Upside V Benchmarks

TypeNameUpside
StockAkoya Biosciences118.18%
SectorHealthcare Stocks 35.25%
IndustryMedical Instruments & Supplies Stocks34.02%

Price Target Trends

1M3M12M
# Anlaysts-17
Avg Price Target-$2.40$4.70
Last Closing Price$1.10$1.10$1.10
Upside/Downside-118.18%327.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25--8--8
Mar, 25116--8
Feb, 25116--8
Jan, 25126--9
Dec, 24145--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2025Piper Sandler$2.40$1.6050.00%118.18%
Nov 15, 2024Dave WestenbergPiper Sandler$4.00$2.3272.41%263.64%
Aug 06, 2024Tejas SavantMorgan Stanley$3.00$2.0149.25%172.73%
Jun 21, 2024Bill BonelloCraig-Hallum$7.50$2.23236.32%581.82%
Jun 03, 2024Tejas SavantMorgan Stanley$4.00$2.1586.05%263.64%
May 14, 2024Mark MassaroBTIG$6.00$4.1245.63%445.45%
May 14, 2024Kyle MiksonCanaccord Genuity$6.00$4.1245.63%445.45%
Aug 17, 2022David WestenbergPiper Sandler$17.00$13.3427.44%1445.45%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2025Piper SandlerOverweightNeutraldowngrade
Nov 15, 2024Piper SandlerOverweightOverweighthold
Aug 06, 2024Morgan StanleyOverweightEqual-Weightdowngrade
Aug 06, 2024BTIGBuyNeutraldowngrade
Jun 21, 2024Craig-HallumBuyinitialise
Jun 03, 2024Morgan StanleyOverweightOverweighthold
May 15, 2024Piper SandlerOverweightOverweighthold
May 14, 2024BTIGBuyBuyhold
May 14, 2024Canaccord GenuityBuyBuyhold
Jan 04, 2023BTIGBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.15$-1.87$-1.43$-1.12----
Avg Forecast$-1.45$-1.78$-1.45$-1.10$-0.62$-0.45$-0.46$-0.37
High Forecast$-1.38$-1.74$-1.30$-1.07$-0.59$-0.35$-0.41$-0.36
Low Forecast$-1.57$-1.83$-1.54$-1.14$-0.66$-0.56$-0.51$-0.38
Surprise %-20.69%5.06%-1.38%1.82%----

Revenue Forecast

$50M $65M $80M $95M $110M $125M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$54.92M$74.86M$96.63M$81.67M----
Avg Forecast$54.44M$74.09M$96.26M$81.85M$91.58M$105.35M$110.90M$120.50M
High Forecast$57.87M$75.64M$96.60M$82.50M$93.55M$105.45M$113.47M$123.30M
Low Forecast$52.41M$72.64M$95.95M$80.68M$90.40M$105.26M$108.63M$118.03M
Surprise %0.88%1.04%0.38%-0.22%----

Net Income Forecast

$-85M $-71M $-57M $-43M $-29M $-15M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-42.94M$-70.64M$-63.32M$-55.37M----
Avg Forecast$-64.46M$-79.27M$-63.32M$-48.91M$-27.88M$-23.45M$-20.44M$-16.44M
High Forecast$-61.34M$-77.26M$-57.75M$-47.37M$-26.37M$-15.39M$-18.22M$-16.00M
Low Forecast$-69.74M$-81.43M$-68.25M$-50.44M$-29.40M$-24.89M$-22.66M$-16.94M
Surprise %-33.39%-10.89%-13.21%----

AKYA Forecast FAQ

Is Akoya Biosciences stock a buy?

Akoya Biosciences stock has a consensus rating of Hold, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Akoya Biosciences is a neutral investment for most analysts.

What is Akoya Biosciences's price target?

Akoya Biosciences's price target, set by 7 Wall Street analysts, averages $2.4 over the next 12 months. The price target range spans from $2.4 at the low end to $2.4 at the high end, suggesting a potential 118.18% change from the previous closing price of $1.1.

How does Akoya Biosciences stock forecast compare to its benchmarks?

Akoya Biosciences's stock forecast shows a 118.18% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the medical instruments & supplies stocks industry (34.02%).

What is the breakdown of analyst ratings for Akoya Biosciences over the past three months?

  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.

What is Akoya Biosciences’s EPS forecast?

Akoya Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.62, marking a -44.64% decrease from the reported $-1.12 in 2024. Estimates for the following years are $-0.45 in 2026, $-0.46 in 2027, and $-0.37 in 2028.

What is Akoya Biosciences’s revenue forecast?

Akoya Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $91.58M, reflecting a 12.14% increase from the reported $81.67M in 2024. The forecast for 2026 is $105.35M, followed by $110.9M for 2027, and $120.5M for 2028.

What is Akoya Biosciences’s net income forecast?

Akoya Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-27.883M, representing a -49.64% decrease from the reported $-55.365M in 2024. Projections indicate $-23.45M in 2026, $-20.44M in 2027, and $-16.441M in 2028.